Precision Optics (US:POCI)2026-02-17 23:02Financial Data and Key Metrics Changes - Revenue for Q2 reached a record $7.4 million, up 64% year-over-year from $4.5 million and up 10% sequentially from $6.7 million [6][23] - Production revenue was approximately $6.4 million, compared to $3.1 million in the year-ago quarter and $6.0 million in the prior sequential quarter [23] - Gross margins were 2.8%, down from 14.2% in the prior sequential quarter and 23.6% in the year-ago quarter [24] - Net loss for the quarter was $1.8 million, compared to $1.0 million in the year-ago quarter and $1.6 million in the sequential first quarter [26] Business Line Data and Key Metrics Changes - Aerospace program generated $2.7 million in revenue during Q2, maintaining high-volume performance [9] - Single-use cystoscope program generated $2.0 million in revenue, up from $1.5 million in Q1, marking the sixth consecutive quarter of record revenue [11] - Engineering revenue was $1 million, down from $1.2 million in the year-ago quarter but up from $700,000 in the previous quarter [23] Market Data and Key Metrics Changes - The market for single-use endoscopes is expected to grow at mid to high teens annual growth rates over the next 10 years [18] - Strong interest in technologies from the defense aerospace market, particularly for next-generation aeronautic and satellite systems [18] Company Strategy and Development Direction - The company is focused on operational improvements and has invested in sales, leadership, and marketing efforts [8] - The production business is expected to create significant value for shareholders over the long term [30] - The company is increasing full-year revenue guidance to a range of $26 million-$28 million, up from $25 million previously estimated [21] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that fiscal 2026 is a transition year, building infrastructure for a larger production business [30] - Positive developments in product development and a rebound in the Ross Optical division are anticipated [15][16] - Management expects to achieve break-even levels of adjusted EBITDA with improvements in production programs [13] Other Important Information - The company has made leadership changes, including the appointment of a new COO to address operational challenges [7] - Cash at the end of December was approximately $900,000, with bank debt at $1.6 million [26] - The company is negotiating to increase the use of debt capital to fund business expansion and working capital needs [27] Q&A Session Summary Question: Can you clarify if the design revisions required to fix yield shortfalls are within your control? - The design change has been approved by the customer, and production is expected to begin in the next month [33] Question: Can you comment on facility changes and when they will be operational? - Facility updates are complete for the main operation, with further updates planned over the next 6-12 months [37] Question: Can you talk about your loan discussions and certainty of reaching positive EBITDA without dilution? - Loan discussions are advanced, and the company is confident in securing funding without significant equity dilution [39] Question: What long-term return is expected on investments in production infrastructure? - Investments in operations and management infrastructure are expected to support significantly higher production revenue [44] Question: Which program is receiving higher than expected order flow? - The aerospace program and the single-use cystoscope are both exceeding original expectations [45]